1 Nod2 protects remote small intestinal sites in case of colonic inflammation. 2 Ziad Al Nabhani^{1,2}, Dominique Berrebi^{1,2,3,\$}, Christine Martinez-Vinson^{3,\$}, Nicolas 3 Montcuquet^{4,5}, Gilles Dietrich⁶, Gurminder Singh⁷, Jerrold R. Turner⁷, Chrystele Madre^{1,2,3}, 4 Maryline Roy^{1,2}, Eric Ogier-Denis^{1,2}, Monique Dussaillant^{1,2,3}, Nadine Cerf-Bensussan^{4,5}, 5 Habib Zouali⁸, Camille Jung^{1,2,3}, Fanny Daniel¹, Frédérick Barreau^{1, 2, 6#}, Jean-Pierre 6 Hugot^{1,2,3#*}. 7 8 9 **Affiliations :** ¹Laboratoire d'excellence Inflamex, Université Paris-Diderot Sorbonne Paris-Cité, UMR 10 11 1149, F-75018 Paris, France. 12 ²INSERM, UMR 1149, F-75018 Paris, France. ³Assistance Publique Hôpitaux de Paris, services des maladies digestives et respiratoires de 13 14 l'enfant et service d'anatomie pathologique, Hôpital Robert Debré, F-75019 Paris, France. 15 ⁴INSERM, UMR 989, F-75015 Paris, France. 16 ⁵Université Paris Descartes – Sorbonne Paris Cité, Institut IMAGINE, F-75015 Paris, France. ⁶IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France. 17 18 ⁷Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, 19 Massachusetts. ⁸Fondation Jean-Dausset CEPH, F-75011 Paris, France. 20 ^{\$ and #}equal contribution 21 22 *Address for correspondence: 23 Prof Jean-Pierre Hugot, 24 INSERM U843, Hôpital Robert Debré, 25 48 Boulevard Sérurier, 75019 Paris, France. 26 Phone : +33 1 40 03 57 12 ; Fax : +33 1 40 03 57 66 27 e-mail : jean-pierre.hugot@rdb.aphp.fr 28 Running title: Nod2 and remote gut protection 29 Key words: Nod2/intestinal permeability/Crohn's disease/gut barrier/myosin light chain 30 kinase/CD4⁺ T cells. Abbreviations: CD: Crohn's disease; IM: intestinal mucosa (without Peyer's patches); MDP: 31 32 Muramyl dipeptide; MLCK: myosin light chain kinase; NOD2: nucleotide oligomerization 33 domain 2; RICK: receptor-interacting serine/threonine kinase; TAK1: transforming growth

- 34 factor β-activated kinase 1; TNBS: 2,4,6-trinitrobenzene sulfonic acid; TNF-R, TNF receptor;
- 35 WT: wild-type.
- 36

37 ABSTRACT

NOD2 mutations are key risk factors for Crohn's disease (CD). NOD2 contributes to 38 39 intestinal homeostasis by regulating innate and adaptive immunity together with intestinal 40 epithelial function. However, the roles of NOD2 during gut inflammation is not known. We 41 initially observed that NOD2 expression was increased in epithelial cells remote from 42 inflamed areas in CD patients. To explore this finding. Nod2 mRNA expression. 43 inflammation and gut permeability were examined in the small bowel of wild-type (WT), 44 Nod2 knockout and Nod2 mutant mice after rectal instillation of 2,4,6-trinitrobenzene sulfonic 45 acid (TNBS). In WT mice, Nod2 upregulation remote to rectal injury was associated with proinflammatory cytokine expression, recirculating CD4⁺ T-cells, increased paracellular 46 47 permeability and myosin like chain kinase activity. Nod2 knockout or mutation led to 48 duodenitis and ileitis demonstrating the remote protective role of Nod2. Bone morrow stem 49 cell (BMSC) transplantations indicated that the small intestinal inflammation was due to 50 NOD2 loss in both hematopoietic and non-hematopoietic compartments. As a whole, WT but 51 not mutant NOD2 prevents disease extension at sites remote from the initial intestinal injury. 52

53

54 Introduction

55 Crohn's Disease (CD) is an inflammatory bowel disease (IBD) that can affect any part 56 of the entire gastrointestinal tract. Genetic and epidemiological studies indicate that CD is a 57 complex, multifactorial disorder. Interplay between genetics and the environment promotes 58 development of gut abnormalities of autophagy, reticulum endoplasmic stress, innate and 59 adaptive immune responses, Th-1 and Th-17 polarization, intestinal barrier dysfunction and 50 microbial dysbiosis.¹⁻³

Nucleotide oligomerization domain 2 (*NOD2*, also known as NLR-C2 and CARD15) is the most prominent susceptibility gene for CD.^{4, 5} One-third to one-half of CD patients have one or more *NOD2* mutations.⁶ Wild-type NOD2 is activated by muramyl dipeptides (MDP) which are components of the bacterial cell wall,⁷ but CD-associated *NOD2* mutations prevent MDP responses.⁸ CD can therefore be considered as an immune deficiency with insufficient responses to bacteria. Nevertheless, the exact mechanism by which *NOD2* mutations contribute to CD pathogenesis remains a matter of debate.⁹⁻¹²

NOD2 regulates innate and adaptive immunity and intestinal permeability to maintain 68 intestinal homeostasis.¹³⁻¹⁶ Indeed, *Nod2* ablation in mice leads to an increased bacterial 69 70 translocation across the small intestinal epithelium and excessive inflammatory cytokine secretion.^{14, 15} This reflects impaired crosstalk between inflammatory cytokine-secreting CD4⁺ 71 T-cells and epithelial cells that express myosin light chain kinase (MLCK).^{15, 17} Similarly, 72 increased MLCK activity¹⁸ and CD4⁺ T-numbers have been observed in the intestinal mucosa 73 of CD patients,^{19, 20} and mouse models show that genetic activation of epithelial MLCK 74 induces increases in mucosal CD4⁺ T-numbers.²¹ Anti-TNF- α antibody treatment restores the 75 intestinal barrier in CD patients.²² Impaired epithelial barrier function may therefore be an 76 77 early event in CD lesions progression.

Here, we show that NOD2 expression in CD patients is not only increased in inflammatory lesions but also at sites remote from injury. To define the mechanisms and impact of this upregulation, we explored the remote consequences on the small intestinal mucosa of a limited rectal injury induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS).

82

Results 83

84

Epithelial NOD2 expression is increased in uninflamed mucosa of CD patients.

85 In CD patients, epithelial NOD2 expression is increased in mildly inflamed areas of the digestive tract, remote from sites of injury.²³ To confirm NOD2 upregulation in remote 86 areas, we examined expression in ileal and/or cecal biopsies from 17 treatment-naïve pediatric 87 88 CD cases and five non-inflammatory controls. Although nine CD patients had heterozygous 89 mutations in NOD2 (1007fs n=3, R702W n=5 and R373C n=1), no histological differences 90 were seen between patients with wild type or mutant NOD2. Immunostains using two 91 different antibodies showed that NOD2 was weakly expressed by surface enterocytes and rare 92 mononuclear cells immediately below the epithelium in control ileum (Figure 1A). In contrast, 93 NOD2 expression was increased in ileum from CD patients (Figure 1B and C). While NOD2 94 expression was upregulated in lamina propria mononuclear cells within inflammatory areas, 95 the most prominent increases were in surface and glandular epithelial cells outside of 96 inflammatory lesions (Figure 1B and C). Analysis of cecal biopsies gave similar results 97 (Figure 1*D*-*F*).

98 We then determined NOD2 mRNA expression in the epithelial and lamina propria 99 compartments by qPCR after laser microdissection of biopsies from 8 patients. We observed 100 that NOD2 mRNA expression was inversely correlated in the epithelial and lamina propria 101 compartments of the same biopsy (Figure 1G). In the lamina propria, the average NOD2 copy 102 number was 43.1 in controls (normalized arbitrary units). In CD patients, similar values (43.6) 103 were observed in uninflamed areas whereas NOD2 expression was increased a 5-fold 104 (205.907) in the inflamed ileum. On the contrary, the mean values were 4.91 in epithelial cells 105 of controls and 4.6 in inflamed ileal areas but a 100-fold increase in NOD2 expression (660) 106 was detected in uninflamed ileum. Noteworthy, normal Paneth cells had low NOD2 107 expression in controls (1.43). This expression was increased by inflammation and in 108 heterotopic colonic Paneth cells but NOD2 was mostly expressed by enterocytes. We thus 109 concluded that NOD2 expression is markedly increased in epithelial cells distant from 110 inflammatory lesions in CD patients.

- 111
- 112

Gut injury leads to epithelial Nod2 expression and cytokine production at remote 113 sites via CD4⁺ T-cell activation.

To confirm the expression of epithelial Nod2 in healthy areas distant from intestinal 114 lesions in a mouse model, we treated *Nod2* wild-type ($Nod2^{WT}$) mice by an intra-rectal 115 administration of TNBS. Instillation of TNBS in mice is known to induce a severe 116

inflammation in the distal colon.¹⁴ Interestingly, TNBS has also been shown to alter the 117 biochemical activity of brush border enzymes (sucrase isomaltase and aminopeptidase), 118 119 mucins and cytokines levels in the small bowel (i.e. at a significant distance from the gut injury) without histological lesions.²⁴ Three days after instillation, mice were sacrificed and 120 the severity of inflammation was assessed (Figure 2). In the distal colon, TNBS 121 122 administration induced a robust inflammation as evidenced by decreased body weight. 123 increased disease activity index (DAI), reduced colon length and high macroscopic Wallace 124 damage scores (Figure 2A-D). Consistent with this phenotype, expression levels of $TNF-\alpha$, 125 IFN- γ and IL-12 were increased (Figure 2*E*) at the site of colonic inflammation.

126 We next examined the small bowel but we did not find any overt inflammatory lesion 127 in the duodenum or ileum (Figure 2F and G) despite increased TNF- α , IFN- γ and IL-12 128 proteins (Figure 2H) and mRNA (Figure 2I) levels. As observed in CD patients, expression of 129 Nod2 was increased in the duodenum, ileum and the uninflamed part of the colon remote from 130 rectal injury (Figure 21). We hypothesized that this effect was consecutive to the recirculation 131 of CD4⁺ pro-inflammatory T-cells in the gut mucosa. We therefore treated TNBS-challenged 132 mice with anti-CD4⁺ monoclonal antibodies to reduce the number of CD4⁺ T-cells in the 133 small bowel (Figure 2J). This treatment only partially improved the colitis but restored 134 normal levels of *Nod2* and inflammatory cytokines in the duodenum and ileum (Figure 2A-I).

135 IFN- γ and TNF- α increase intestinal paracellular permeability via MLCK activation. We therefore investigated whether the paracellular permeability of the small bowel was 136 affected in TNBS treated mice.²⁵⁻²⁷ Paracellular permeability as well as long Mylk mRNA 137 expression were increased in both duodenum and ileum but returned to normal after CD4⁺ T-138 139 cell depletion (Figures 2*I* and *K*). Treatment of mice with an inhibitor of inflammatory $CD4^+$ 140 T-cells recirculation (FTY720) limited paracellular permeability increases in the duodenum 141 and the ileum further indicating that a recirculation of T-cells from the rectal inflammatory 142 lesions is likely responsible for the remote small bowel barrier loss (Figure 2L).

Of note, given the abundance of immune cells in inflamed areas, higher levels of epithelial NOD2 would be expected in the inflamed bowel of CD patients if the expression of epithelial *NOD2* was under the control of $CD4^+$ T-cells. We therefore determined the populations of immune cells present in the lamina propria of CD patients by immunostaining. Consistent with data collected in mice, lamina propria $CD4^+$ T-cell numbers were not increased in areas with the highest grades of inflammation. Most immune cells present in the lamina propria at these sites within the ileum (Figures 3*A* and *B*) and the colon (Figure 3*C* and

150 *D*) were CD163⁺ macrophages. Consistently, CD4⁺ T-cells predominated in areas with low 151 grade inflammation.

- 152
- 153

MLCK activity is necessary to maintain the pro-inflammatory status of the small

154 *intestinal mucosa.*

155 Since pro-inflammatory cytokines such as IL-1 β , TNF- α and IFN- γ can alter the 156 paracellular permeability of the intestinal epithelium by increasing the expression and activity of long MLCK, we explored the role of MLCK in barrier function.^{17, 27-30} Treatment of mice 157 with ML-7 (an inhibitor of MLCK) had only a limited impact on the severity of TNBS-158 159 induced colitis (Figure 4A-E). In contrast, MLCK inhibition restored normal TNF- α , IFN- γ , IL-1β, IL-12 expression (mRNA and protein), Mylk and Nod2 mRNA transcription, and 160 161 paracellular permeability in the duodenum and the ileum (Figures 4F-H). Similarly, knockout 162 mice lacking long MLCK developed a slightly less severe colitis compared to WT mice 163 (Figure 4*I*-L) and did not develop increased duodenal or ileal paracellular permeability 164 (Figure 4*M*). These data confirm that MLCK activity is responsible for the gut barrier defect 165 remote from inflammatory lesions.

166

167

NOD2 maintains the barrier integrity on remote small bowel.

168 We have previously shown that stimulation of epithelial NOD2 with MDP allows the maintenance of the gut barrier.¹⁷ Nod2^{WT} mice were treated with MDP for 2 consecutive days 169 170 before experimentation. Intraperitoneal injection of rhodamine-labelled MDP confirmed the 171 ability of MDP to enter the enterocytes (Figures 5A-C). NOD2 stimulation reduced the 172 disease activity index, colonic length, Wallace damage scores and pro-inflammatory cytokine 173 expression without any effects on body weight loss after rectal TNBS infusion (Figures 5D-174 H). In contrast, in the small bowel, MDP treatment normalized mRNA (Figure 51) and protein 175 (Figure 5J) levels of pro-inflammatory cytokines as well as the paracellular permeability 176 (Figure 5K). As expected, MDP did not affect the increase in Nod2 expression (Figure 5I).

177 Ablation of *Nod2* in mice (*Nod2*^{KO}) results in increased paracellular and transcellular 178 permeability across Peyer's patches^{14, 15} and higher percentages of pro-inflammatory CD4⁺ T-179 cells¹⁴ but *Nod2*^{KO} mice are only slightly more susceptible to TNBS-induced colitis (Figures 180 6A-D).¹⁴ However, while TNBS-treated *Nod2*^{WT} mice exhibit no lesion in the small bowel 181 (Figure 2*F*), two thirds of *Nod2*^{KO} mice showed overt duodenal inflammatory lesions as 182 shown by a slight infiltration of scattered neutrophils in the *lamina propria* (Figure 6*E and F*). In the ileum, we observed a marked inflammation in 5/8 *Nod2*^{KO} mice, an infiltration of neutrophils and mononuclear cells in the villi and the crypts and a loss of muco-secretion. In addition, $Nod2^{KO}$ mice exhibited an increased expression of pro-inflammatory cytokines in the duodenum and the ileum (Figure 6*G*). In contrast to $Nod2^{WT}$ mice, treatment with MDP did not correct the expression of pro-inflammatory cytokines nor the increased permeability in the intestine of $Nod2^{KO}$ mice (Figures 7*A*-*F*). These findings indicate that the absence of Nod2leads to the development of remote lesions distant to rectal injury.

190 In humans, CD is characterized by gastrointestinal skip lesions. Among the NOD2 genetic polymorphisms associated with CD, the 3020insC mutation encodes for a truncated 191 (1007fs) protein. As described in $Nod2^{KO}$ mice, $Nod2^{2939insC}$ mice -which are homozygotes for 192 a mutation homologous to the Human 3020insC variant¹² -developed a slightly more severe 193 194 colitis after TNBS administration (Figure 6A-D). We observed inflammatory lesions in the duodenum and ileum of respectively 4/5 and 6/8 Nod2^{2939insC} mice after TNBS instillation 195 (Figures 6E and F). Treatment of $Nod2^{2939insC}$ mice with MDP did not reduce the expression 196 197 of pro-inflammatory cytokines and the increased permeability in the small intestine (Figure 198 7A-F). We thus concluded that mice carrying a CD associated mutation of NOD2 are not able 199 to contain the intestinal inflammation where the primitive inflammatory lesions occurred.¹²

Since $Nod2^{KO}$ mice present a microbiota dysbiosis, we studied the contribution of gut microbiota in the inflammatory phenotype using littermate mice cohoused for 6 weeks.³¹⁻³⁴ Sharing the dysbiotic microbiota associated with the deletion of Nod2 in $Nod2^{WT}$ mice did not change the severity of TNBS-induced colitis (Figures 7*G*-*H*) and the increased paracellular permeability of the ileal mucosa (Figure 7*I*). This finding suggests that the microbiota plays no major role on remote intestinal sites.

- 206
- 207 208

Both hematopoietic and non-hematopoietic Nod2 regulate the small bowel function remote from colonic injury.

NOD2 is detected in intestinal cells of hematopoietic and non-hematopoietic-origins.³⁵ 209 210 To compare the role of hematopoietic vs non-hematopoietic NOD2 in the small bowel during 211 colitis, we compared Nod2 chimeric mice after bone marrow stem cell (BMSC) transfer from $Nod2^{KO}$ to $Nod2^{WT}$ mice (KO \rightarrow WT) and $Nod2^{WT}$ to $Nod2^{KO}$ (WT \rightarrow KO) to control mice 212 213 transplanted with BMSC of the same genetic background (WT \rightarrow WT and KO \rightarrow KO) (Figures 8A-C).³² Chimeric mice were then challenged with TNBS three months after BMSC 214 transplantation. Chimeric mice transplanted with Nod2^{KO} BMSC were slightly more 215 susceptible to TNBS-induced colitis than chimeric mice grafted with *Nod2*^{WT} BMSC (Figures 216 8D-H).¹⁷ Indeed, body weight loss, DAI and colonic length were similar between mice 217

receiving WT (WT→WT and WT→KO chimeric mice altogether referred to WT→WT/KO mice) or *Nod2*^{KO} bone morrow (KO→KO and KO→WT chimeric mice referred to KO→KO/WT mice). However, the Wallace score, IFN- γ and TNF- α levels were higher in colonic inflamed mucosae of chimeric mice receiving *Nod2*^{KO} BMSC compared to mice receiving *Nod2*^{WT} BMSC (Figures 8*D*-*H*).

223 Interestingly, ablation of Nod2 in the hematopoietic lineages led to a more frequent 224 and more severe inflammation in the ileum compared to chimeric mice expressing Nod2 in 225 the hematopoietic cells (Figure 81). In parallel, expression levels of pro-inflammatory 226 cytokines levels and paracellular permeability were higher in mice deficient for Nod2 in 227 BMSC (Figures 8J and K). Consistent with the anti-inflammatory role of NOD2 in the intestinal mucosa³⁶, treatment with MDP improved the colonic inflammation but also the 228 severity of the small bowel inflammation and the expression in inflammatory cytokines in the 229 230 ileum only in chimeric mice expressing Nod2 in their hematopoietic compartment (Figures 231 8H-J). However, chimeric mice expressing NOD2 in their radio-resistant compartment 232 showed reduced paracellular permeability after MDP treatment regardless of the presence of 233 NOD2 in hematopoietic cells (Figure 8K). This provides additional evidence that both 234 hematopoietic and non-hematopoietic NOD2 exerts a protective function on the gut barrier.¹⁷

235

236 **Discussion**

A "leaky gut" is a common feature of several conditions associated with *NOD2* mutations including CD. Here we show that NOD2 protects the small intestine not only in injured areas but also in areas remote from gut mucosal lesions. Indeed, NOD2 controls the paracellular permeability all along the digestive tract to contain the inflammation to local injuries and prevents its dissemination throughout the intestine.

We first observed that NOD2 expression was increased remote from primary inflammatory lesions in naïve pediatric CD patients. Interestingly, the increase in NOD2 expression was not restricted to immune cells in inflammatory areas as it was also detected in epithelial cells remote from CD lesions. We therefore hypothesized that epithelial NOD2 may have a specific role in healthy intestinal areas and explored the intestinal barrier remote from local injuries in mice.

The TNBS-induced colitis is a well-known model of self-limited inflammation. Although TNBS is administered in the rectum, it also alters the small intestine without any overt histological lesions in rats suggesting a remote effect of the colitis on the upper

intestine.^{24, 37} In wild-type mice, we did not find any overt duodenitis or ileitis but we 251 252 observed an increase in pro-inflammatory cytokines (TNF- α and IFN- γ) concentration, 253 intestinal permeability and epithelial Nod2 expression in the small bowel. These effects were 254 reversed by anti-CD4⁺ antibodies or inhibitor of recirculated CD4⁺ T -cells suggesting that 255 they were consecutive to the recirculation of T-cells activated in the injured mucosa. 256 Pharmacologic or genetic MLCK inhibition limited permeability increases, indicating that 257 MLCK activation is a key component of the inflammatory response. Specifically, gut permeability augmented TNF- α and IFN- γ expression and altered lamina propria immune 258 status.²¹ Conversely, pro-inflammatory cytokines increased paracellular permeability by 259 stimulating MLCK expression and activity.^{28, 29} 260

Local colonic injury leads to the disruption of the small bowel barrier. Since Nod2 is 261 known to protect the gut barrier by inhibiting MLCK¹⁵ and because it was over-expressed in 262 the small intestine, we supposed that it could restrain the leaky gut phenotype to the injured 263 264 mucosa. MDP-induced activation of Nod2 fully corrected the impairment of the small bowel 265 indicating that Nod2 plays a protective role along the small bowel. Recirculation of activated 266 T-cells increases the gut permeability but also induces NOD2 expression which, in turn, 267 strengthens the gut barrier. Interestingly, NOD2 seems to have little effect on the colitis itself. 268 The severity of the inflammation may thus limit the effect of Nod2.

In contrast to WT mice, *Nod2*-deficient or mutated mice developed overt inflammatory lesions in the small bowel during TNBS-induced colitis, thus confirming the relevance of NOD2 in the protection of the gut barrier. Using BMSC transfer experiments (from *Nod2*^{WT} to *Nod2*^{KO} mice and vice-versa), we showed that both hematopoietic and nonhematopoietic NOD2 are necessary to protect the small bowel mucosa.

274 To the best of our knowledge, the role of NOD2 remote to colonic inflammation had 275 never been demonstrated. In CD, Th-1 oriented CD4⁺ T cells appear to be key effectors of gut inflammation and NOD2 expression³⁸ and most treatments (anti-inflammatory drugs, 276 immune-suppressors and anti-TNF- α antibodies) target CD4⁺ T cells. For instance, TNF- α 277 antagonists diminish the severity of the disease and restore the gut barrier function.^{22, 39} In our 278 279 model, Nod2 invalidation in the hematopoietic compartment is sufficient to promote a barrier 280 defect which is consistent with reported cases of CD patients cured by allogenic or autologous hematopoietic stem cell transplantation.⁴⁰ However, activation of epithelial NOD2 may also 281 counteract the effect of IFN- γ and TNF- α suggesting that treatment of patients not carrying 282 283 mutations in NOD2 with NOD2 agonists could activate the negative feedback loop to prevent the propagation of the inflammation and the skip lesions defining CD.⁴¹ 284

285

286 Material and Methods

287 **Patients and biopsies.**

288 Intestinal biopsies were obtained from 17 untreated children during routine endoscopies 289 performed to establish CD diagnosis. Controls were histologically normal digestive biopsies 290 obtained from 5 children without inflammatory bowel disease. For each participant, one or 291 two biopsies from the ileum and/or cecum were sampled. Biopsies were either immediately 292 frozen and later stained with toluidine blue or fixed in 4%-phosphate-buffered formalin and 293 stained with hematoxylin and eosin. All biopsies were graded histologically so that 294 immunohistochemistry and laser microdissection could be correlated with disease severity. 295 NOD2 immunostaining was performed as previously described with two different rabbit polyclonal antibodies (Cayman Chemical and a gift from G Thomas CEPH).²³ Laser 296 microdissection was performed on 7µm sections obtained from the frozen biopsies. After 297 298 verification of the quality of tissues and the absence of ulcers, surface epithelial cells and lamina propria cells were laser-microdissected using a Leica^R AS LMD system (Leica 299 300 microsystems) in less than one hour. A mean of 500 cells were microdissected from each of the specimens (range 100-1000 cells) and stored in Trizol^R reagent (Invitrogen, Groningen, 301 The Netherlands). The study was approved by the ethic committee "de protection des 302 303 personnes" (Saint Louis Hospital, Paris, France) and all the parents of participants provided a 304 signed informed consent.

305 Animal models.

306 Housing and experiments were conducted according to institutional animal healthcare 307 guidelines and were approved by the local ethical committee for animal experimentation 308 (Comité Régional d'Ethique en matière d'Expérimentation Animale no. 4, Paris, France). C57BL/6 wild-type (WT). Nod2 null allele (Nod2^{KO}) and Nod2^{2939insC} mice (homozygotes for 309 a mutation homologous to the Human 3020insC variant) together with long MLCK deficient 310 mice (MLCK^{KO}) were generated or hosted in a pathogen free animal facility.^{12, 14, 26} The 311 312 animal facility was monitored every six months in accordance with the full set of FELASA 313 high standard recommendations. The putative impact of Nod2-related dysbiosis on the studied phenotypes was assessed using WT and $Nod2^{KO}$ mice cohoused for 6 weeks in the same cage 314 where indicated.^{33, 42} 315

For the construction of chimeric mice, five million bone marrow stem cells (BMSC) were isolated from WT Ly5.1 or *Nod2*^{KO}Ly5.2 mice and injected intravenously either into 318 WT Ly5.1 or *Nod2*^{KO}Ly.5.2 lethally-irradiated recipients.^{30, 32} Chimerism was verified at 319 week 12 by flow cytometry using Ly5.1 and Ly5.2 congenic markers (Figure 8A-C).³⁵

320 $CD4^+$ T-cells were depleted by two intra-peritoneal (i.p.) injections of 100µg purified 321 GK1.5 (anti-L3T4 (CD4⁺) monoclonal antibody (Pharmingen, Germany), 96 and 24 hours 322 before experimentation and 24hours after TNBS administration.¹⁵ The effectiveness of CD4 + 323 depletion in Peyer's plates is shown in Figure 2*J*. To inhibit the recirculation of CD4⁺ T-cells, 324 mice were treated i.p. with FTY720 (3mg/kg; Sigma, France)⁴³ 0, 1, 2 and 3 days after TNBS 325 infusion.

- MLCK inhibition was achieved by ip injection of ML-7, 2 mg/kg body weight (Sigma, France) twice daily during 4 days before experiments and 24 hours after TNBS administration.¹⁵ To investigate the effect of Nod2 stimulation, adult mice were pre-treated i.p with muramyl dipeptide (MDP, 100µg/mice/day; Sigma, France) for 2 consecutive days before experimentation and 24 hours after TNBS administration.³⁵
- 331 Colitis induction.

332 Colitis was induced in 12 weeks old mice by a single intra-rectal administration of 333 2,4,6-trinitrobenzene sulfonic acid (TNBS, Sigma, France), which was dissolved in ethanol 334 (50:50 vol/vol) at a dose of 120 mg/kg body weight under anaesthesia. Groups used as 335 controls (vehicle) received an equal volume of PBS and Ethanol (50:50 vol/vol) intra-rectally. 336 A 100 µl aliquot of the freshly prepared solution was injected into the colon, 4 cm from the anus, using a 3.5 F polyethylene catheter as previously described.¹⁴ Body weight loss and 337 338 disease activity index were monitored before and 72h after TNBS administration. Mice were 339 sacrificed by cervical dislocation. Colonic length and macroscopic damage Wallace score were recorded.44 340

341 Duodenal and ileal samples were fixed in 4%-phosphate-buffered formalin and 342 embedded in paraffin. Five-micrometer sections were cut and stained with hematoxylin and eosin. Grading of the inflammatory scores were performed in blind fashion according the follow 343 criteria⁴⁵: 0, no sign of inflammation; 1, very low level of leukocyte infiltration; 2, low level 344 345 of leukocyte infiltration; 3, high level of leukocyte infiltration, high vascular density, and 346 thickening of the colon wall; 4, transmural infiltration, loss of goblet cells, high vascular 347 density, and thickening of the colon wall in less than half of circumference ; 5 necrosis of 348 more than half the circumference and transmural inflammation.

Myeloperoxydase (MPO) expression was detected by immunohistochemistry. All sections were deparaffinized in xylene, rehydrated, incubated in 3% hydrogen peroxide for endogenous peroxidase removal, and heated for 10 minutes in sub-boiling 10 mM citrate

buffer (pH 6.0) for antigen retrieval. Then, sections were processed using the ImmPRESS
polymer detection systems & reagents (Vector Laboratories, Burlingame, Ca), using antiMPO antibody (Abcam, Cambridge, UK).

355

Muramyl dipeptide localization.

356 Mice were injected intraperitoneally with 300µg of rhodamine-labeled muramyl 357 dipeptide (MDP, InvivoGen, San Diego, CA). Two hours later, mice were anesthetized with 358 isofurane (Centre Specialités Pharmaceutiques, Moussy-le-Neuf, France) and sacrified. Ileal 359 and duodenal samples were collected and rinsed with ice-cold PBS (ThermoFisher, Waltham, 360 MA). Tissue was frozen in liquid nitrogen using HistoLab OCT cryomount (Histolab, 361 Gothengurg, Sweden), 10µm-thick cryosections were cut and then fixed in 4%. PFA. MDP-362 rhodamine localization was detected by fluorescence confocal microscopy (confocal sp8, 363 Leica, Frankfurt am Main, Germany).

364

Paracellular permeability measurement.

To measure the intestinal permeability, biopsies from duodenal and ileal mucosa were mounted in a Ussing chamber exposing 0.196 cm² of tissue surface to 1.5ml of circulating oxygenated Ringer solution at 37°C. Paracellular permeability was assessed by measuring the mucosal-to-serosal flux of 4 kDa FITC-dextran (Sigma, France).³⁰

369 ELISA.

Biopsies of duodenum, ileum and colon from different mice models were collected and washed with cold PBS. These biopsies were then homogenized using an ultra-thurax in 1 ml of PBS1X and, the concentration of protein was determined using commercial kit (Biorad, Marnes la Coquette, France). IFN- γ , IL-1 β , IL-12 and TNF- α protein levels in the intestine were determined by ELISA according to manufacturer's instructions (BD Biosciences).⁴⁶

375

DNA extraction and real time quantitative PCR.

376 After extraction by the NucleoSpin RNA II Kit (Macherey-Nagel, France), total RNAs 377 were converted to cDNA using random hexonucleotides and then used for RT-PCR 378 (Invitrogen). We conducted qPCR with QuantiTect SYBR Green PCR Kit (Applied, France) 379 using sense and antisense primers specific for G3PDH, the long MLCK isoform (specifically 380 expressed by epithelial cells), Ifn-y, Il-1 β , Il-12, NOD2, Mylk and Tnf- α (primers used 381 available in table 1). The cycle threshold (Ct) was defined as the number of cycles at which 382 the normalized fluorescent intensity passed the level of 10 times the standard deviations of the baseline emission calculated on the first 10 PCR cycles. Results are expressed as $2^{-\Delta\Delta Ct}$ as 383 previously described.³³ For RNA samples obtained by laser microdissection, NOD2 384 385 expression was measured in triplicate and normalized using the Abelson housekeeping gene. 386 To derive a relative number of mRNA molecules, a titration curve was established with 387 NOD2 plasmids (from 1 to 10^6 copy/microliters).

388 Statistical analysis.

For all the analysis, multigroup comparisons were performed using one-way ANOVA statistics with Bonferroni correction for multiple comparisons where an unpaired t-test assuming the Gaussian distribution was applied. The Gaussian distribution was tested by the Kolmogorov-Smirnov test. Statistical analyzes were performed using GraphPad Prism 7.00 (GraphPad Software). A two-sided P-value < 0.05 was considered statistically significant. All authors reviewed the data and approved the final manuscript.

395

396 Acknowledgements.

We thank Latifa Ferkdadji, Michel Peuchmaur, Xavier Fund, Anh Thu Gaston,
Guillaume Even and Céline Berraud for their support and assistance. Financial support was
provided by INSERM, Université Paris Diderot, Assistance Publique Hopitaux de Paris,
Association François Aupetit and Investissements d'Avenir programme ANR-11-IDEX-000502, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX and NIH grant NIDDK
DK061931/DK068271.

403

404 Author contributions:

Study design and concept: ZA, DB, HZ, FB, JPH; Data acquisition: ZA, DB, CMV, NM, CM,
MR, MD, HZ, CJ, FB; Analysis and interpretation: ZA, DB, CMV, NM, GD, JRT, CM, MR,
NCB, CJ, FB, JPH; Writing of the manuscript: ZA, GD, JRT, NCB, FB, JPH; Obtained
funding: JPH; Technical support: DB, CMV, GS, GD, NM, CM, MR, EOD, MD, CJ; Study
supervision: DB, FB, JPH.

410

411 Authors have no conflict of interest to declare.

- 412
- 413

References.

- Treton X, Pedruzzi E, Guichard C, Ladeiro Y, Sedghi S, Vallee M, Fernandez N, Bruyere E, Woerther PL, Ducroc R, Montcuquet N, Freund JN, Van Seuningen I, Barreau F, Marah A, Hugot JP, Cazals-Hatem D, Bouhnik Y, Daniel F, Ogier-Denis E. Combined nadph oxidase 1 and interleukin 10 deficiency induces chronic endoplasmic reticulum stress and causes ulcerative colitis-like disease in mice. PLoS One 2014;9:e101669.
- 2. Thachil E, Hugot JP, Arbeille B, Paris R, Grodet A, Peuchmaur M, Codogno P, Barreau F, Ogier-Denis E, Berrebi D, Viala J. Abnormal activation of autophagyinduced crinophagy in paneth cells from patients with crohn's disease. Gastroenterology 2012.
- 3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-17.
- 4. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of nod2 leucine-rich repeat variants with susceptibility to crohn's disease. Nature 2001;411:599-603.
- 5. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. A frameshift mutation in nod2 associated with susceptibility to crohn's disease. Nature 2001;411:603-6.
- Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O'Morain C, Gassull M, Binder V, Finkel Y, Modigliani R, Gower-Rousseau C, Macry J, Merlin F, Chamaillard M, Jannot AS, Thomas G, Hugot JP. Card15/nod2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845-57.
- 7. Al Nabhani Z, Dietrich G, Hugot JP, Barreau F. Nod2: The intestinal gate keeper. PLoS Pathog 2017;13:e1006177.
- 8. Inohara N, Nunez G. Nods: Intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003;3:371-82.
- 9. Watanabe T, Kitani A, Murray PJ, Strober W. Nod2 is a negative regulator of toll-like receptor 2-mediated t helper type 1 responses. Nat Immunol 2004;5:800-8.
- 10. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, Flavell RA. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731-4.
- 11. Eckmann L, Karin M. Nod2 and crohn's disease: Loss or gain of function? Immunity 2005;22:661-7.
- 12. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, Eckmann L, Karin M. Nod2 mutation in crohn's disease potentiates nf-kappab activity and il-1beta processing. Science 2005;307:734-8.
- Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, Kuechler I, Krueger S, Schmidt HH, Lochs H. Genetic basis for increased intestinal permeability in families with crohn's disease: Role of card15 3020insc mutation? Gut 2006;55:342-7.
- Barreau F, Meinzer U, Chareyre F, Berrebi D, Niwa-Kawakita M, Dussaillant M, Foligne B, Ollendorff V, Heyman M, Bonacorsi S, Lesuffleur T, Sterkers G, Giovannini M, Hugot JP. Card15/nod2 is required for peyer's patches homeostasis in mice. PLoS One 2007;2:e523.

- 15. Barreau F, Madre C, Meinzer U, Berrebi D, Dussaillant M, Merlin F, Eckmann L, Karin M, Sterkers G, Bonacorsi S, Lesuffleur T, Hugot JP. Nod2 regulates the host response towards microflora by modulating t cell function and epithelial permeability in mouse peyer's patches. Gut 2010;59:207-17.
- 16. Barreau F, Hugot J. Intestinal barrier dysfunction triggered by invasive bacteria. Curr Opin Microbiol 2014;17C:91-98.
- 17. Al Nabhani Z, Montcuquet N, Roy M, Dussaillant M, Hugot JP, Barreau F. Complementary roles of nod2 in hematopoietic and nonhematopoietic cells in preventing gut barrier dysfunction dependent on mlck activity. Inflamm Bowel Dis 2017;23:1109-1119.
- 18. Blair SA, Kane SV, Clayburgh DR, Turner JR. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest 2006;86:191-201.
- 19. Reikvam DH, Perminow G, Lyckander LG, Gran JM, Brandtzaeg P, Vatn M, Carlsen HS. Increase of regulatory t cells in ileal mucosa of untreated pediatric crohn's disease patients. Scand J Gastroenterol 2011;46:550-60.
- 20. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, Maggi E, Pupilli C, Tonelli F, Romagnani S. Type 1 t-helper cell predominance and interleukin-12 expression in the gut of patients with crohn's disease. Am J Pathol 1997;150:823-32.
- 21. Su L, Shen L, Clayburgh DR, Nalle SC, Sullivan EA, Meddings JB, Abraham C, Turner JR. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 2009;136:551-63.
- 22. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Rutgeerts P. Anti-tumor necrosis factor treatment restores the gut barrier in crohn's disease. Am J Gastroenterol 2002;97:2000-4.
- 23. Berrebi D, Maudinas R, Hugot JP, Chamaillard M, Chareyre F, De Lagausie P, Yang C, Desreumaux P, Giovannini M, Cezard JP, Zouali H, Emilie D, Peuchmaur M. Card15 gene overexpression in mononuclear and epithelial cells of the inflamed crohn's disease colon. Gut 2003;52:840-6.
- 24. Barada KA, Mourad FH, Sawah SI, Khoury C, Safieh-Garabedian B, Nassar CF, Saade NE. Localized colonic inflammation increases cytokine levels in distant small intestinal segments in the rat. Life Sci 2006;79:2032-42.
- 25. Zolotarevsky Y, Hecht G, Koutsouris A, Gonzalez DE, Quan C, Tom J, Mrsny RJ, Turner JR. A membrane-permeant peptide that inhibits mlc kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 2002;123:163-72.
- 26. Clayburgh DR, Barrett TA, Tang Y, Meddings JB, Van Eldik LJ, Watterson DM, Clarke LL, Mrsny RJ, Turner JR. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates t cell activation-induced diarrhea in vivo. J Clin Invest 2005;115:2702-15.
- 27. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferongamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 2005;166:409-19.
- 28. Al-Sadi R, Ye D, Dokladny K, Ma TY. Mechanism of il-1beta-induced increase in intestinal epithelial tight junction permeability. J Immunol 2008;180:5653-61.
- 29. Wang F, Schwarz BT, Graham WV, Wang Y, Su L, Clayburgh DR, Abraham C, Turner JR. Ifn-gamma-induced tnfr2 expression is required for tnf-dependent intestinal epithelial barrier dysfunction. Gastroenterology 2006;131:1153-63.

- 30. Jung C, Meinzer U, Montcuquet N, Thachil E, Chateau D, Thiebaut R, Roy M, Alnabhani Z, Berrebi D, Dussaillant M, Pedruzzi E, Thenet S, Cerf-Bensussan N, Hugot JP, Barreau F. Yersinia pseudotuberculosis disrupts intestinal barrier integrity through hematopoietic tlr-2 signaling. J Clin Invest 2012;122:2239-51.
- Mondot S, Barreau F, Al Nabhani Z, Dussaillant M, Le Roux K, Dore J, Leclerc M, Hugot JP, Lepage P. Altered gut microbiota composition in immune-impaired nod2(-/-) mice. Gut 2012;61:634-5.
- 32. Alnabhani Z, Hugot JP, Montcuquet N, Le Roux K, Dussaillant M, Roy M, Leclerc M, Cerf-Bensussan N, Lepage P, Barreau F. Respective roles of hematopoietic and nonhematopoietic nod2 on the gut microbiota and mucosal homeostasis. Inflamm Bowel Dis 2016;22:763-73.
- 33. Al Nabhani Z, Lepage P, Mauny P, Montcuquet N, Roy M, Le Roux K, Dussaillant M, Berrebi D, Hugot JP, Barreau F. Nod2 deficiency leads to a specific and transmissible mucosa-associated microbial dysbiosis which is independent of the mucosal barrier defect. J Crohns Colitis 2016;10:1428-1436.
- 34. Couturier-Maillard A, Secher T, Rehman A, Normand S, De Arcangelis A, Haesler R, Huot L, Grandjean T, Bressenot A, Delanoye-Crespin A, Gaillot O, Schreiber S, Lemoine Y, Ryffel B, Hot D, Nunez G, Chen G, Rosenstiel P, Chamaillard M. Nod2mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 2013.
- 35. Alnabhani Z, Montcuquet N, Biaggini K, Dussaillant M, Roy M, Ogier-Denis E, Madi A, Jallane A, Feuilloley M, Hugot JP, Connil N, Barreau F. Pseudomonas fluorescens alters the intestinal barrier function by modulating il-1beta expression through hematopoietic nod2 signaling. Inflamm Bowel Dis 2015;21:543-55.
- 36. Brain O, Owens BM, Pichulik T, Allan P, Khatamzas E, Leslie A, Steevels T, Sharma S, Mayer A, Catuneanu AM, Morton V, Sun MY, Jewell D, Coccia M, Harrison O, Maloy K, Schonefeldt S, Bornschein S, Liston A, Simmons A. The intracellular sensor nod2 induces microrna-29 expression in human dendritic cells to limit il-23 release. Immunity 2013;39:521-36.
- 37. Amit-Romach E, Reifen R, Uni Z. Mucosal function in rat jejunum and ileum is altered by induction of colitis. Int J Mol Med 2006;18:721-7.
- 38. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011;140:1756-67.
- 39. Brown GR, Lindberg G, Meddings J, Silva M, Beutler B, Thiele D. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology 1999;116:593-601.
- 40. Leung Y, Geddes M, Storek J, Panaccione R, Beck PL. Hematopoietic cell transplantation for crohn's disease; is it time? World J Gastroenterol 2006;12:6665-73.
- 41. Rosenstiel P, Fantini M, Brautigam K, Kuhbacher T, Waetzig GH, Seegert D, Schreiber S. Tnf-alpha and ifn-gamma regulate the expression of the nod2 (card15) gene in human intestinal epithelial cells. Gastroenterology 2003;124:1001-9.
- 42. Robertson SJ, Zhou JY, Geddes K, Rubino SJ, Cho JH, Girardin SE, Philpott DJ. Nod1 and nod2 signaling does not alter the composition of intestinal bacterial communities at homeostasis. Gut Microbes 2013;4:222-31.
- 43. Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, Stein JM. Fty720 ameliorates th1-mediated colitis in mice by directly affecting the functional activity of cd4+cd25+ regulatory t cells. J Immunol 2007;178:2458-68.
- 44. Wallace JL, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 1990;258:G527-34.

- 45. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
- 46. Meinzer U, Barreau F, Esmiol-Welterlin S, Jung C, Villard C, Leger T, Ben-Mkaddem S, Berrebi D, Dussaillant M, Alnabhani Z, Roy M, Bonacorsi S, Wolf-Watz H, Perroy J, Ollendorff V, Hugot JP. Yersinia pseudotuberculosis effector yopj subverts the nod2/rick/tak1 pathway and activates caspase-1 to induce intestinal barrier dysfunction. Cell Host Microbe 2012;11:337-51.

Figures legend.

Figure 1: NOD2 expression in increased in intestinal mucosa of Crohn disease patients.

(A-F) Biopsies from controls (A and D) and naïve pediatric CD patients (B, C, E and F) were immunostained with anti-NOD2 antibodies. Ileal (A-C) or cecal (D-F) biopsies were obtained from inflamed (C and F) or uninflamed areas (B and E). Data shown are representative of 5 controls and 17 CD patients. (G) Number of NOD2 mRNA copies were normalized by the expression of Abelson gene and expressed as arbitrary units. mRNA levels were calculated for the epithelial monolayer (in blue) and the lamina propria (in red) from the same biopsy after laser microdissection. Biopsies were obtained from inflamed or uninflamed intestinal areas and referenced by an arbitrary number.

Figure 2: Remote gut barrier dysfunctions of the small intestine are mediated by recirculating CD4⁺ T-cells.

(*A-L*) C57BL/6 wild-type mice (*Nod*2^{WT}) were instilled intra-rectally with TNBS. Vehicle control group was challenged by PBS-Ethanol. Mice were treated with anti-CD4⁺ antibodies or FTY720, an inhibitor of T-cell recirculation where indicated. 3 days after the instillation, the intensity of the colitis was monitored with the following parameters: (*A*) Weight loss; (*B*) Disease activity index; (*C*) Colonic length (cm); (*D*) Colonic macroscopic score (Wallace score); (*E*) Pro-inflammatory cytokine levels in inflamed colon. In parallel, the duodenum and ileum were explored by microscopic examination after (F) hematoxylin-eosin staining and (G) Myeloperoxidase (MPO) immunostaining (colonic MPO expression in a mouse treated with DSS 3% for 7 days is shown as a positive inflammatory control); H) Protein levels of pro-inflammatory cytokines; (I) mRNA expressions of pro-inflammatory cytokines, *Mlyk* and *Nod2*; (J) levels of CD4⁺ T-cells in ileal Peyer's patches after CD4⁺ depletion with anti-CD4⁺ antibodies; (K-L) Paracellular permeability assessed by Ussing chamber experiments. Original magnification, X20. Scale bars: 100µM. (Each point = one mice ; mean±s.e.m; 3 independent experiments; *P<0.05, *P<0.01 and ****P<0.001 vs. vehicle control group or indicated group; +*P<0.01 vs. TNBS group).

Figure 3: CD4 and CD163 immunostaining of ileal and colonic biopsies from CD patients.

(*A-B*) Ileal and (*C-D*) colonic biopsies were collected from uninflamed or inflamed locations in CD patients. (*A* and *C*) Grading of the inflammation was confirmed by coloration by hematoxylin-eosin (HES) and CD4⁺ or CD163⁺ positive cells were assessed by immunostaining. (*B* and *D*) CD4⁺ or CD163⁺ positive cells were counted in the lamina propria. (At least n=6 fields per patients; mean \pm SEM; *P<0.05 vs. uninflamed CD4⁺ T-cells; +P<0.05 and ⁺⁺⁺P<0.001 vs. uninflamed CD163⁺ T-cells). Areas with lymphoid follicles were excluded.

Figure 4: Inhibition of MLCK prevents the small bowel alteration triggered by TNBS induced colitis.

(*A-M*) Colitis was induced by intra-rectal administration of TNBS in (A-H) wild-type (WT) mice or (I-M) long isoform MLCK knock-out (MLCK^{KO}) mice while the control group was challenged with PBS-Ethanol. Mice were treated with ML-7, an MLCK inhibitor, or PBS (Vehicle) where indicated. 3 days after induction of colitis, the following parameters were monitored to evaluate the severity of the colitis : (*A*,*I*) Weight loss and (*B*,*J*) Disease activity index; (*C*,*K*) Colonic length; (*D*,*L*) Wallace score; (*E*) Levels of pro-inflammatory cytokine in inflamed colon. In parallel, the following parameters were measured in the duodenum and ileum: (*F*) protein levels and; (*G*) mRNA expression of pro-inflammatory cytokines, *Mylk* and *Nod2*; (*H*,*M*) Paracellular permeability. (One point = one mouse; mean \pm s.e.m; 3 independent experiments; ^{*}P<0.05, ^{**}P<0.01 and ^{***}P<0.001 vs. vehicle control group or indicated group; ⁺⁺P<0.01 vs. TNBS group; ns=non-significant).

Figure 5: NOD2 activation reverses the remote effects of TNBS-induced colitis.

(A-C) Localization of muramyl dipeptide (MDP) in the small intestine after intraperitoneal injection. Rhodamine-labeled MDP is detected in epithelial cells of the small intestine two hours after IP injection. Fluorescence (red) was detected in epithelial cells of the (*B*) duodenum and (*C*) ileum. Nuclei were stained with DAPI (blue). (*A*) The ileum of a mouse injected with distilled water was used as a negative control. Original magnification, X40. Scale bars: 100µM. (*D-K*) C57BL/6 wild-type mice were instilled intra-rectally with TNBS. Vehicle control group was challenged with PBS-Ethanol. Mice were treated with MDP where indicated. 3 days after induction, the colitis was monitored by the following parameters: (*D*) Disease activity index; (*E*) Colonic length; (*F*) Wallace score; (*G*) levels of pro-inflammatory

cytokines in inflamed colon; (*H*) Weight loss. In parallel, the following measures were made in the duodenum and ileum: (*I*) mRNA expression of pro-inflammatory cytokines, *Mylk* and *Nod2*; (*J*) protein expression of pro-inflammatory cytokines; (*K*) Paracellular permeability. (Each point = one mouse; mean \pm s.e.m; 3 independent experiments; *P<0.05, **P<0.01 and ***P<0.001 vs. vehicle group or indicated group; *P<0.05, **P<0.01 and **P<0.001 vs. TNBS vehicle group).

Figure 6: TNBS induced colitis leads to small bowel inflammation in *Nod2* deficient or mutated mice.

(*A-F*) $Nod2^{WT}$, $Nod2^{KO}$ and $Nod2^{2939insC}$ mice were challenged by intra-rectal instillation of TNBS. 3 days after induction, the colitis was monitored with the following parameters: (*A*) Weight loss; (*B*) Disease activity index; (*C*) Colonic length; (*D*) Wallace score. In parallel, the duodenum and ileum were studied by: (*E* and *F*) microscopic examination after hematoxylineosin staining; (*G*) protein levels of pro-inflammatory cytokines. (One point = one mouse; mean \pm s.e.m; 3 independent experiments; ^{**}P<0.01 and ^{***}P<0.001 vs. Vehicle group; ⁺⁺P<0.01 vs. indicated group; ns=non-significant).

Figure 7: The small bowel is not protected by muramyl dipeptide in Nod2 deficient mice. The gut microbiota does not play a major role.

(*A-E*) $Nod2^{WT}$, $Nod2^{KO}$ and $Nod2^{2939insC}$ mice were challenged by intra-rectal instillation of TNBS. Mice were treated with muramyl dipeptide (MDP) or PBS (vehicle) where indicated. (*A*) Disease activity index; (*B*) Colonic length; (*C*) Wallace score; Levels of pro-inflammatory cytokine in the (D) colon or (E) small bowel. (F) paracellular permeability in the small bowel. (G-I). $Nod2^{WT}$ and $Nod2^{KO}$ mice were left separated or co-housed for at least 6 weeks to homogenize their microbiota. 3 days after TNBS-colitis induction, the following parameters were monitored: (G) Colonic length; (H) Colonic macroscopic score (Wallace score) and; (I) ileal Paracellular permeability (One point = one mouse; mean ± s.e.m; 3 independent experiments; *P<0.05 and **P<0.01 vs. indicated group; +P<0.05, ++P<0.05 and +++P<0.001 vs. instilled TNBS $Nod2^{WT}$ group).


Figure 8: Both hematopoietic and non-hematopoietic *Nod2* regulate the small bowel function remote from gut injury.


(A-C) Chimeric mice were generated by transplantation of BMSC mice from $Nod2^{WT}$ to


Nod2^{KO} (WT \rightarrow KO) or from Nod2^{KO} to *Nod2*^{WT}(KO \rightarrow WT). Mice transplanted with BMSC of the same genetic background (WT \rightarrow WT or KO \rightarrow KO) served as controls. Where indicated WT \rightarrow KO and WT \rightarrow WT (respectively KO \rightarrow WT and KO \rightarrow KO) were pooled and annotated $WT \rightarrow WT/KO$ (respectively KO $\rightarrow WT/KO$). Three months after bone marrow transplantation, chimerism for CD45 isoforms expression was monitored in Peyer's patches of chimeric mice via flow cytometry. (A) Percentages of CD45.1 and CD45.2 positive cells. (B and C) Percentages of CD3⁺, CD19⁺ and CD11c⁺ cells in CD45Ly5.1 or CD45Ly5.2 respectively. (D-K) Three month after transplantation, colitis was induced by intra-rectal administration of TNBS. Mice were treated with MDP or PBS (vehicle) where indicated. 3 days after induction of colitis, the following parameters were monitored: (D) Weight loss; (E) Disease activity index; (F) Wallace score; (G) colonic length; (H) levels of pro-inflammatory cytokines in inflamed colon. In the ileum, the following parameters were recorded in parallel: (1) microscopic score; (J) Levels of pro-inflammatory cytokines and; (K) Paracellular permeability. (At least n=6 per group; mean \pm s.e.m; data show a combination of two independent experiments: $^{*}P<0.05$, $^{**}P<0.01$ and $^{***}P<0.001$ vs. indicated group: $^{+}P<0.05$. ⁺⁺P<0.01 and ⁺⁺⁺P<0.001 vs. instilled TNBS control group; ns=non-significant).


mRNA	Sense	Antisense
long MLCK isoform	5'-ACATGCTACTGAGTGGCCTCTCT-3'	5'GGCAGACAGGACATTGTTTAAGG-3'
IL-1β	5'-CAACCAACAAGTGATATTCTCCATG-3'	5'- GATCCACACTCTCCAGCTGCA-3'
IL-12	5'-ACGAGAGTTGCCTGGCTACTAG-3'	5'-CCTCATAGATGCTACCAAGGCAC-3'
IFN-γ	5'-CAGCAACAGCAAGGCGAAAAAGG-3'	5'-TTTCCGCTTCCTGAGGCTGGAT-3'
TNF-α	5'-CATCTTCTCAAAATTCGAGTGACAA-3'	5'-TGGGAGTAGACAAGGTACAACCC-3'
Nod2	5'-GCCAGTACGAGTGTGAGGAG -3'	5'-CCCTGACGTGCTGTAGAAGG-3'


Table 1. List of primers used for qPCR analyses in mice.

















○ Nod2^{WT} ■ Nod2^{KO} ◆ Nod2^{2939insC}

